Prevalence, awareness, treatment, and control of type 2 diabetes mellitus among the adult residents of Tehran: Tehran Cohort Study

Alireza Oraii1†, Akbar Shafiee1†, Arash Jalali1*, Farshid Alaeddini1, Soheil Saadat2, Farzad Masoudkabir1,3, Ali Vasheghani-Farahani1,3, Amirhossein Heidari3,4, Saeed Sadeghian1, Mohamamdali Boroumand1, Abbasali Karimi1 and Oscar H. Franco5

Abstract

Background: The prevalence of type 2 diabetes mellitus has increased in the past decades. We investigated the prevalence of diabetes and its awareness, treatment, and control among adult residents of Tehran.

Methods: We used the recruitment phase data of the Tehran Cohort study, enrolling a random sample of adult residents of Tehran aged ≥35 years. Diabetes was defined as self-report, current use of glucose-lowering medications, and/or fasting plasma glucose (FPG) ≥126mg/dl. Impaired fasting glucose (IFG) was defined as an FPG of 100-125mg/dl. Awareness was defined as diabetes self-report, treatment as receiving glucose-lowering medications, and glycemic control as FPG <126mg/dl. The age- and sex-weighted estimates were calculated using the 2016 national census. Logistic regression models were used to determine the factors associated with diabetes awareness, treatment, and control.

Results: A total of 8151 participants were included. Age- and sex-weighted prevalence of diabetes mellitus and IFG were 16.7% (95% CI: 15.1–18.4) and 25.1% (95% CI: 23.1–27.1), respectively. Diabetes was more prevalent in the eastern and central districts of Tehran. Advanced age (OR per 1-year increase: 1.026, 95% CI: 1.021–1.030), male sex (OR: 1.716, 95% CI: 1.543–1.909), higher BMI levels (OR for BMI ≥35 vs. <20 kg/m²: 4.852, 95% CI: 3.365-6.998), pre-existing hypertension (OR: 1.552, 95% CI: 1.378-1.747), dyslipidemia (OR: 1.692, 95% CI: 1.521-1.883), and chronic kidney disease (OR: 1.650, 95% CI: 1.019-2.673) were associated with an increased odds of diabetes mellitus. On the contrary, diabetes mellitus was less likely in current tobacco (OR: 0.872, 95% CI: 0.765-0.994) and alcohol users (OR: 0.836, 95% CI: 0.703-0.994) compared to non-users. Among diabetic individuals, 82.8% were aware of their condition, 71.9% received treatment, and 31.7% of treated patients had adequate glycemic control. Advanced age and pre-existing comorbidities, including hypertension and dyslipidemia, were associated with higher diabetes awareness and treatment.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Type 2 diabetes mellitus is one of the major global health concerns of the 21st century. The International Diabetes Federation estimates that 9.3% of adults aged 20-79 (463 million people) have diabetes, which is projected to reach 578 million adults by 2030 [1]. The 2017 Global Burden of Diseases studies further estimated that high fasting plasma glucose (FPG) was the third most common global risk factor for disability-adjusted life years [2]. Notably, diabetes mellitus is an important risk factor for cardiovascular diseases [3–5]. This signifies the vital role of up-to-date epidemiological studies in designing national and local health policies.

The age-standardized diabetes prevalence in adults has increased globally over the past decades [6]. The increase in diabetes burden and number of adults with diabetes was more substantial in low- and middle-income countries than in high-income countries. Population aging, urbanization, sedentary lifestyle, and unhealthy dietary habits have been proposed as major drivers of this increasing trend [7]. Similarly, the number of diabetic patients has been rising among the Iranian population for the past 20 years [8]. A recent study showed a prevalence of 15.0% for diabetes mellitus and 25.4% for prediabetes in some provinces of Iran that did not encompass Tehran [9]. However, there is a considerable variation in the prevalence of diabetes between different geographical regions of the country [10–12].

Tehran, the capital of Iran, is a heavily populated metropolis with over eight million individuals. Although there has been an increasing trend of diabetes in Tehran [13], few epidemiological studies have described its prevalence in Tehran. These studies are limited by district-level sampling, specific patient populations, and/or methods of diagnosing diabetes mellitus [14, 15]. Therefore, one cannot judge the accurate prevalence of known cases of diabetes as well as newly diagnosed cases among the adult population of Tehran. Additionally, the rate of awareness, treatment, and glycemic control of people with type 2 diabetes in Tehran remains unclear and requires further investigation.

The lack of up-to-date data regarding the prevalence, awareness, treatment, and glycemic control of diabetes in Tehran warrants a comprehensive epidemiological study on these issues. Such data can be implemented in future health policies and public health interventions to reduce the diabetes burden and associated disabilities. Therefore, we aimed to determine the prevalence of diabetes mellitus type 2 and its awareness, treatment, and control rate among adult residents of Tehran, utilizing data from the Tehran Cohort study (TeCS).

Methods
Study design and participants
In the present study, we analyzed data from TeCS, a population-based prospective study of adult residents of Tehran, a heavily-populated metropolitan area in the Middle East. The study protocol of TeCS has been published in detail elsewhere [16]. In brief, a sample of adult residents of Tehran aged ≥35 years were enrolled through a systematic random sampling method. A total of 4215 households comprising 8296 adults aged ≥35 years participated in the study between May 2016 and February 2019. Participants lacking data regarding self-report of a previous diagnosis of diabetes, medication history, and/or FPG, as well as type 1 diabetes mellitus, were excluded from the present study (n=145). In the end, data from 8151 participants were included for further analyses. The research deputy and the ethical committee of the Tehran University of Medical Sciences approved the study protocol (IR.TUMS.MEDICINE.REC.1399.074). Additionally, all participants signed a written informed consent before enrollment.

Data collection and measurements
Data regarding demographic characteristics, pre-existing comorbidities, metabolic and behavioral risk factors, physical activity, and level of education were gathered through detailed in-person interviews. Furthermore, standard anthropometric indices, including weight, height, and waist and hip circumference, were measured in all participants. Body mass index (BMI) was calculated as weight divided by the square of height (kg/m²). Waist circumference was measured at the top of the iliac crest at the approximate level of the umbilicus, and hip circumference was taken around the widest portion of the buttocks. A fasting venous blood sample was obtained to measure FPG level after an overnight fast of 8-12 hours.
Definitions
We used the standard criteria laid by the World Health Organization and International Diabetes Federation for defining type 2 diabetes mellitus and glycemic control [17]. Diabetes mellitus was defined as having any of the following: 1) self-report of a previous diagnosis of type 2 diabetes mellitus by healthcare providers, 2) current use of any glucose-lowering medications including oral hypoglycemic agents or insulin, or 3) an FPG of ≥126 mg/dl after an overnight fast of 8-12 hours. Impaired fasting glucose (IFG) was defined as an FPG of 100 to 125 mg/dl without a previous diagnosis of type 2 diabetes or the current use of glucose-lowering medication. According to the above criteria, participants with abnormal glucose metabolism were defined as having either diabetes mellitus or IFG. Individuals with either self-reported diabetes or current use of glucose-lowering medications were considered as known cases of diabetes. In contrast, those without a self-report of diabetes or medication use in whom a diagnosis of diabetes was made based on our laboratory measurement of FPG were considered new cases of diabetes. Awareness was defined as a self-report of a previous diagnosis of diabetes and treatment as a self-report of receiving any glucose-lowering medication among diabetic participants. Glycemic control was also defined as an FPG of less than 126 mg/dl among diabetic participants under treatment [17].

Pre-existing comorbidities included hypertension, dyslipidemia, or chronic kidney disease, defined as the previous diagnosis of the condition or related medication use. Definitions of tobacco use, opium consumption, and alcohol use were described in our study protocol previously [16]. In brief, current tobacco use was considered daily or occasional cigarette, pipe, or hookah smoking. Former tobacco users were those with a history of smoking who had quit for at least one month before the interview. Opium consumption was defined as any use of opium or its derivatives in the previous year. Alcohol consumption was considered as any use of alcoholic products within the preceding year. Physical activity was categorized as low, intermediate, and high activity based on a Likert-scale questionnaire.

Statistical analyses
Categorical variables were reported as the frequency with percentage and were compared between groups using the chi-square test or Fisher exact test. Continuous data were expressed as mean with standard deviation or median (interquartile range boundaries) according to the normality distribution of data. An independent student t-test was used to compare continuous data between two groups. Due to different age and sex distribution in our study population compared with the adult population of Tehran, age- and sex-weighted rates were calculated for the prevalence of diabetes and IFG in the overall study population, using Tehran's adult population aged ≥35 years derived from the 2016 national census. Moreover, the age-weighted prevalence of diabetes and IFG were calculated for men and women. The prevalence of diabetes, awareness, treatment, and control among various age, sex, BMI, metabolic risk factor, physical activity, and education subgroups were further analyzed to examine variations of mentioned indices by different subpopulations. We assessed the effect of baseline covariates on the odds of having diabetes mellitus and abnormal glucose metabolism using a generalized logistic regression model for ordinal dependent variables adjusting for age, sex, marital status, level of education, BMI categories, hypertension, dyslipidemia, chronic kidney disease, physical activity level, tobacco use, alcohol, and opium consumption. This model estimates the partial proportional odds assumption, relaxing the parallel lines assumption for all independent variables. Furthermore, we assessed the determinants of awareness, treatment, and glycemic control among diabetic participants using a logistic regression model including all of the abovementioned baseline covariates. The household code was entered in all models to adjust for potential cluster effects. Odds ratio (OR) with an associated 95% confidence interval (CI) was used for reporting the adjusted effects. All statistical analyses were performed using the IBM SPSS Statistics for Windows, v.25.0 (IBM Corp., Armonk, NY, USA) and STATA version 14.2 (College Station, TX: Stata Corp LP). A p-value of <0.05 was considered statistically significant. The Geographical distribution of diabetes, IFG, awareness, treatment, and sufficient control were depicted in the Tehran map using the first three digits of the postal code using shp2dta and spmap modules in STATA version 14.2 (College Station, TX: Stata Corp LP).

Results
Data from 8151 participants were included in the present study. The mean age of the study population was 53.7 ± 12.73 years, and 4420 (54.2%) participants were women. Of the study population, 71.9% had a BMI of ≥25 kg/m2, 17.6% reported low daily physical activity, and 99.2% were married. A detailed description of the total study population characteristics is shown in Supplementary Table 1.

Prevalence of type 2 diabetes mellitus and impaired fasting glucose
The study participants were categorized into diabetes mellitus, IFG, or normal. A total of 1295 (15.9%) participants had a previous diagnosis of type 2 diabetes mellitus or received glucose-lowering medication (Fig. 1).
Considering the participants having an FPG $\geq 126$ mg/dl, the number of diabetics increased to 1504 (18.5%). Overall, the calculated age- and sex-weighted prevalence of diabetes was 16.7% (95% CI: 15.1 – 18.4) among adult residents of Tehran aged $\geq 35$ years. The age-weighted prevalence of type 2 diabetes mellitus was 16.8% (95% CI: 14.2 – 19.1) in men and 16.6% (95% CI: 14.6 – 19.2) in women. In addition, a total of 2084 (25.6%) participants had IFG based on the obtained blood samples, which would result in an age- and sex-weighted IFG prevalence of 25.1% (95% CI: 23.1 – 27.1) among adult residents of Tehran aged $\geq 35$ years. The age-weighted prevalence of IFG was 29.3% (95% CI: 26.3 – 32.5) in men and 21.7% (95% CI: 19.1 – 24.4) in women. As depicted in Fig 2, the prevalence of diabetes was higher in the Eastern and Central parts of Tehran, and IFG was more observed in the Central and Northern regions.

A detailed descriptive report of the prevalence of diabetes mellitus and IFG across baseline characteristic subgroups is shown in 1. The mean age of diabetic individuals was $60.7 \pm 11.33$ years, and the prevalence of diabetes increased considerably with advancing age, from 5.4% in individuals aged between 35-44 years to 32.4% in those over 75 years (Supplementary Table 2, Fig. 3a). The mean age of participants with IFG was $54.7 \pm 12.03$ years, significantly lower than diabetic individuals ($P$-value <0.001). IFG increased with advancing age to peak in participants aged 45-54 years and showed a decreasing trend in the following age categories (Supplementary Table 2, Fig. 3b).

Detailed associations between baseline characteristics and diabetes mellitus are shown in 2. The multivariable-adjusted model showed that advancing age (OR per 1-year increase 1.026, 95% CI: 1.021-1.030) and male sex (OR 1.716, 95% CI: 1.543-1.909) were significantly associated with higher odds of having diabetes mellitus. A higher level of BMI was associated with higher odds for diabetes mellitus (OR for BMI $\geq 35$ vs. <20 kg/m$^2$: 4.852, 95% CI: 3.365-6.998). In addition, participants with pre-existing hypertension (OR 1.552, 95% CI: 1.378-1.747), dyslipidemia (OR 1.692, 95% CI: 1.521-1.883), or chronic kidney disease (OR 1.650, 95% CI: 1.019-2.673) were more likely to have diabetes mellitus. On the other hand, We observed lower odds of diabetes mellitus in current tobacco users (OR 0.872, 95% CI: 0.765-0.994) and alcohol users (OR 0.836, 95% CI: 0.703-0.994) compared to non-users. Nevertheless, we did not observe any significant association between diabetes mellitus and level of education, physical activity, and opium consumption.

The associations between baseline characteristics and abnormal glucose metabolism were similar to the above-mentioned relationships for diabetes mellitus (2), except for participants with high physical activity levels who had a lower odds of abnormal glucose metabolism (OR 0.678, 95% CI: 0.562-0.819) compared to low active individuals.

**Awareness, treatment, and control of type 2 diabetes mellitus**

**Awareness**

We identified 209 cases with an elevated FPG with no history of diabetes mellitus. Meanwhile, 51 participants took glucose-lowering medications without reporting a history of diabetes mellitus. Hence, in the total of 1504
diabetic participants in our study, 1244 (82.8%) diabetic participants were aware of their diabetes status. A descriptive report of diabetes awareness across baseline characteristic subgroups is shown in 3. In our study population, awareness was lowest among younger individuals but significantly improved with advancing age (35-44 years: 68.5% vs. ≥75 years: 89.4%). Awareness was similar in men and women with an established diagnosis of diabetes mellitus (81.1% vs. 84.2%, respectively) (Supplementary Table 3, Fig. 4a).

The adjustment model showed significantly higher odds of diabetes awareness among diabetic participants aged 65-74 years (OR 1.955, 95% CI: 1.116-3.425) and ≥75 years (OR 2.104, 95% CI: 1.043-4.246) compared to those aged 35-45 years. In addition, pre-existing history of hypertension (OR 1.548, 95% CI: 1.120-2.141) and dyslipidemia (OR 2.212, 95% CI: 1.649-2.967) were associated with an improved awareness among diabetic individuals. However, there was no significant association between diabetes awareness and sex, marital status, BMI, pre-existing chronic kidney disease, level of education, physical activity, tobacco use, alcohol, and opium consumption (3). Awareness of diabetes was more frequent among

Fig. 2 Geographic distribution of the prevalence of (a) diabetes mellitus, and (b) impaired fasting glucose based on the postal regions of Tehran.
Fig. 3  Prevalence of (a) diabetes mellitus and (b) impaired fasting glucose stratified by age and sex
Fig. 4 Prevalence of diabetes mellitus (a) Awareness, (b) Treatment, and (c) Control among treated diabetic individuals stratified by age and sex
Fig. 5 Geographic distribution of diabetes mellitus (a) Awareness, (b) Treatment, and (c) Control among treated diabetic individuals based on the postal regions of Tehran
Table 1  Baseline characteristics and prevalence of diabetes mellitus in the population of Tehran Cohort Study

|                        | Normal*  | Impaired Fasting Glucose* | Diabetes Mellitus* | p-value ‡ |
|------------------------|----------|---------------------------|--------------------|-----------|
| Age, mean ± SD, year   | 50.9 ± 12.51 | 54.7 ± 12.03               | 60.7 ± 11.33       | <0.001    |
| Age, year, n (%)       |          |                           |                    |           |
| 35-44                  | 1715 (74.5) | 463 (20.1)                | 125 (5.4)          |           |
| 45-54                  | 1245 (57.2) | 627 (28.8)                | 305 (14.0)         |           |
| 55-64                  | 870 (45.3)  | 541 (28.1)                | 511 (26.6)         |           |
| 65-74                  | 496 (41.5)  | 315 (26.4)                | 383 (32.1)         |           |
| ≥75                    | 237 (42.7)  | 138 (24.9)                | 180 (32.4)         |           |
| Sex, n (%)             |          |                           |                    | <0.001    |
| Men                    | 1929 (51.7) | 1104 (29.6)               | 698 (18.7)         |           |
| Women                  | 2634 (59.6) | 980 (22.2)                | 806 (18.2)         |           |
| Marital status, n (%)  |          |                           |                    | 0.786     |
| Married                | 4511 (55.9) | 2066 (25.6)               | 1489 (18.5)        |           |
| Non-married            | 37 (56.1)  | 15 (22.7)                 | 14 (21.2)          |           |
| Education, year, n (%) |          |                           |                    | <0.001    |
| Illiterate             | 271 (47.4)  | 120 (21.0)                | 181 (31.6)         |           |
| 1-5                    | 389 (47.2)  | 221 (26.8)                | 215 (26.1)         |           |
| 6-12                   | 2304 (54.5) | 1128 (26.7)               | 799 (18.9)         |           |
| >12                    | 1581 (63.2) | 612 (24.5)                | 307 (12.3)         |           |
| Waist circumference, mean ± SD, cm | 93.6 ±11.26 | 98.6 ±11.37 | 101.2 ±11.63 | <0.001 |
| Hip circumference, mean ± SD, cm | 103.9 ±9.47 | 106.3 ±9.72 | 107.6 ±10.84 | <0.001 |
| Body mass index, kg/m², n (%) |        |                           |                    | <0.001    |
| <20                    | 171 (77.0)  | 39 (17.6)                 | 12 (5.4)           |           |
| 20-24.9                | 1361 (66.6) | 420 (20.5)                | 263 (12.9)         |           |
| 25-29.9                | 1886 (55.9) | 898 (26.6)                | 589 (17.5)         |           |
| 30-34.9                | 843 (47.8)  | 512 (29.0)                | 406 (23.1)         |           |
| ≥35                    | 265 (39.6)  | 197 (29.4)                | 207 (30.9)         |           |
| Hypertension, n (%)    |          |                           |                    | <0.001    |
| No                     | 3685 (63.0) | 1486 (25.4)               | 674 (11.5)         |           |
| Yes                    | 863 (37.8)  | 594 (26.0)                | 829 (36.3)         |           |
| Dyslipidemia, n (%)    |          |                           |                    | <0.001    |
| No                     | 3456 (63.1) | 1439 (26.3)               | 584 (10.7)         |           |
| Yes                    | 1091 (41.2) | 641 (24.2)                | 919 (34.7)         |           |
| Chronic kidney disease, n (%) | | | | <0.001 |
| No                     | 4543 (56.2) | 2069 (25.6)               | 1468 (18.2)        |           |
| Yes                    | 20 (28.2)   | 15 (21.1)                 | 36 (50.7)          |           |
| Tobacco user, n (%)    |          |                           |                    | <0.001    |
| Current                | 930 (59.1)  | 409 (26.0)                | 234 (14.9)         |           |
| Former                 | 139 (43.0)  | 94 (29.1)                 | 90 (27.9)          |           |
| Never                  | 3476 (55.8) | 1576 (25.3)               | 1179 (18.9)        |           |
| Opium consumption, n (%) |        |                           |                    | 0.566     |
| No                     | 4304 (56.1) | 1956 (25.5)               | 1415 (18.4)        |           |
| Yes                    | 229 (53.5)  | 117 (27.3)                | 82 (19.2)          |           |
| Alcohol consumption, n (%) |        |                           |                    | 0.008     |
| No                     | 4091 (55.6) | 1882 (25.6)               | 1391 (18.9)        |           |
| Yes                    | 441 (60.2)  | 185 (25.3)                | 106 (14.5)         |           |
| Physical activity, n (%) |        |                           |                    | <0.001    |
| Low                    | 678 (47.6)  | 355 (24.9)                | 391 (27.5)         |           |
| Intermediate           | 2636 (56.3) | 1174 (25.1)               | 869 (18.6)         |           |
| High                   | 1209 (61.4) | 530 (26.9)                | 229 (11.6)         |           |

Abbreviations: SD Standard deviation
* Percentages are calculated in rows
‡ P-value is calculated between normal, impaired fasting glucose, and diabetes subgroups
diabetic participants living in the Northeast and Southeast districts of Tehran (Fig. 5a).

**Treatment**

In the present study, treatment with glucose-lowering medications was reported in 1080 (71.9%) diabetic participants, which comprised 83.4% of cases with known diabetes. Among treated participants, 865 (80.1%) received oral hypoglycemic agents, 97 (9.0%) received insulin, and 118 (10.9%) received both oral agents and insulin for the treatment of hyperglycemia. A descriptive report of receiving treatment for diabetes across baseline characteristic subgroups is shown in 3. The proportion of individuals receiving glucose-lowering medication increased considerably with advancing age (35-44 years: 52.4% vs. ≥75 years: 83.3%), while no significant difference was observed between men and women (71.3% vs. 72.3%, respectively) (Supplementary Table-3, Fig. 4b).

In the adjusted model, the odds ratio of receiving glucose-lowering medications for the treatment of diabetes was significantly higher among participants aged 55-64 years (OR 1.719, 95% CI: 1.093-2.703), 65-74 years (OR 1.955, 95% CI: 1.196-3.195), and ≥75 years (OR 2.538, 95% CI: 1.380-4.666) compared to younger individuals (3). Pre-existing comorbidities, including hypertension (OR 1.552, 95% CI: 1.378-1.747) and dyslipidemia (OR 1.692, 1.521-1.883), were independent predictors of receiving treatment. However, no significant association was found between receiving treatment and sex, marital status, level of education, BMI level, physical activity, tobacco use, alcohol, and opium consumption (3). Diabetic participants residing in Tehran’s Northern

**Table 2** Determinants of diabetes mellitus and abnormal glucose metabolism in the Tehran Cohort Study

|                      | Diabetes Mellitus |                      | Abnormal Glucose Metabolism (Diabetes Mellitus + IFG) |                      |
|----------------------|-------------------|----------------------|------------------------------------------------------|----------------------|
|                      | Adjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
| **Age, per 1-year increase** | 1.026 (1.021-1.030) | <0.001 | 1.035 (1.029-1.041) | <0.001 |
| **Male sex** | 1.716 (1.543-1.909) | <0.001 | 1.411 (1.236-1.609) | <0.001 |
| **Married** | 0.953 (0.566-1.604) | 0.858 | 0.953 (0.566-1.604) | 0.858 |
| **Education, year** |                      |           |                      |           |
| Illiterate               | Ref.               |           | Ref.                 |           |
| 1-5                     | 1.226 (0.987-1.523) | 0.064 | 1.226 (0.987-1.523) | 0.064 |
| 6-12                    | 1.218 (1.010-1.468) | 0.039 | 1.218 (1.010-1.468) | 0.039 |
| >12                     | 0.932 (0.761-1.140) | 0.496 | 0.932 (0.761-1.140) | 0.496 |
| **Body mass index, kg/m²** |                      |           |                      |           |
| <20                     | Ref.               |           | Ref.                 |           |
| 20-24.9                 | 1.730 (1.226-2.440) | 0.002 | 2.143 (1.493-3.077) | <0.001 |
| 25-29.9                 | 2.543 (1.813-3.566) | <0.001 | 2.543 (1.813-3.566) | <0.001 |
| 30-34.9                 | 3.313 (2.346-4.679) | <0.001 | 3.313 (2.346-4.679) | <0.001 |
| ≥35                     | 4.853 (3.365-6.998) | <0.001 | 4.853 (3.365-6.998) | <0.001 |
| **Hypertension** | 1.552 (1.378-1.747) | <0.001 | 1.918 (1.671-2.201) | <0.001 |
| **Dyslipidemia** | 1.692 (1.521-1.883) | <0.001 | 2.826 (2.483-3.216) | <0.001 |
| **Chronic kidney disease** | 1.650 (1.019-2.673) | 0.042 | 1.650 (1.019-2.673) | 0.042 |
| **Tobacco user** |                      |           |                      |           |
| Never                  | Ref.               |           | Ref.                 |           |
| Former                 | 1.117 (0.886-1.410) | 0.347 | 1.117 (0.886-1.410) | 0.347 |
| Current                | 0.872 (0.765-0.994) | 0.041 | 0.872 (0.765-0.994) | 0.041 |
| **Opium consumption** | 0.936 (0.757-1.158) | 0.545 | 0.936 (0.757-1.158) | 0.545 |
| **Alcohol consumption** | 0.836 (0.703-0.994) | 0.043 | 0.836 (0.703-0.994) | 0.043 |
| **Physical activity** |                      |           |                      |           |
| Low                    | Ref.               |           | Ref.                 |           |
| Intermediate           | 0.943 (0.833-1.067) | 0.358 | 0.943 (0.833-1.067) | 0.358 |
| High                   | 0.894 (0.769-1.039) | 0.147 | 0.678 (0.562-0.819) | <0.001 |

Abbreviations: OR Odds ratio, CI Confidence interval

All variables are included in the multivariable logistic regression model for calculating the adjusted odds ratios.
### Table 3 Determinants of diabetes awareness, treatment, and glycemic control among the diabetic population of Tehran Cohort Study

|                          | Awareness<sup>a</sup> | Treatment<sup>a</sup> | Control among treated<sup>a</sup> |
|--------------------------|-----------------------|-----------------------|-----------------------------------|
|                          | n = 1244 (82.8%)      | n = 1080 (71.9%)      | n = 342 (31.3%)                   |
|                          | n (%)                  | Adjusted OR (95% CI)  | p-value                           |
|                          |                        | n (%)                  | Adjusted OR (95% CI)  | p-value                           |
|                          |                        | n (%)                  | Adjusted OR (95% CI)  | p-value                           |
| Age, year                |                        |                        |                                   |
| 35-44                    | 85 (68.5)              | Ref.                   | 65 (52.4)                         | Ref.                               |
| 45-54                    | 239 (78.4)             | 1.448 (0.871-2.407)   | 0.153                             | 197 (64.6)                        | 1.409 (0.890-2.229)   | 0.143                             |
| 55-64                    | 434 (83.8)             | 1.491 (0.908-2.446)   | 0.114                             | 371 (72.6)                        | 1.719 (1.093-2.703)   | 0.019                             |
| 65-74                    | 335 (87.5)             | 1.955 (1.116-3.425)   | 0.019                             | 297 (77.5)                        | 1.955 (1.196-3.195)   | 0.007                             |
| ≥75                      | 161 (89.4)             | 2.104 (1.043-4.246)   | 0.038                             | 150 (83.3)                        | 2.538 (1.380-4.666)   | 0.003                             |
| Sex                      |                        |                        |                                   |
| Men                      | 566 (81.1)             | Ref.                   | 498 (71.3)                        | Ref.                               |
| Women                    | 678 (84.2)             | 1.137 (0.811-1.594)   | 0.455                             | 582 (72.3)                        | 0.878 (0.664-1.161)   | 0.363                             |
| Marital status           |                        |                        |                                   |
| Non-married              | 162 (89.5)             | Ref.                   | 147 (81.2)                        | Ref.                               |
| Married                  | 253 (82.4)             | 1.046 (0.565-1.936)   | 0.884                             | 220 (71.7)                        | 0.966 (0.546-1.650)   | 0.704                             |
| Body mass index, kg/m²   |                        |                        |                                   |
| <20                      | 11 (91.7)              | Ref.                   | 10 (83.3)                         | Ref.                               |
| 20-24.9                  | 230 (87.5)             | 0.487 (0.053-4.405)   | 0.522                             | 203 (77.2)                        | 0.483 (0.090-2.581)   | 0.395                             |
| 25-29.9                  | 489 (83.8)             | 0.316 (0.035-2.800)   | 0.902                             | 419 (71.1)                        | 0.333 (0.063-1.743)   | 0.193                             |
| ≥30                      | 331 (81.1)             | 0.258 (0.029-3.04)    | 0.226                             | 285 (69.9)                        | 0.318 (0.060-1.671)   | 0.176                             |
| Hypertension             |                        |                        |                                   |
| No                       | 516 (76.6)             | Ref.                   | 427 (63.4)                        | Ref.                               |
| Yes                      | 728 (87.8)             | 1.548 (1.120-2.141)   | 0.008                             | 653 (78.8)                        | 1.502 (1.159-1.946)   | 0.002                             |
| Dyslipidemia             |                        |                        |                                   |
| No                       | 433 (74.1)             | Ref.                   | 360 (61.6)                        | Ref.                               |
| Yes                      | 811 (88.2)             | 2.212 (1.649-2.967)   | <0.001                            | 720 (78.3)                        | 1.999 (1.558-2.565)   | <0.001                            |
| Chronic kidney disease   |                        |                        |                                   |
| No                       | 1209 (82.4)            | Ref.                   | 1048 (71.4)                       | Ref.                               |
| Yes                      | 35 (97.2)              | 4.494 (0.657-30.733)  | 0.125                             | 32 (88.9)                         | 1.859 (0.604-5.722)   | 0.280                             |
| Tobacco user             |                        |                        |                                   |
| Current                  | 187 (79.9)             | Ref.                   | 158 (67.5)                        | Ref.                               |
| Former                   | 75 (83.3)              | 0.914 (0.481-1.736)   | 0.784                             | 67 (74.4)                         | 0.946 (0.548-1.631)   | 0.842                             |
| Never                    | 982 (83.3)             | 1.119 (0.729-1.717)   | 0.607                             | 855 (72.5)                        | 0.999 (0.697-1.433)   | 0.999                             |
| Opium consumption        |                        |                        |                                   |
| No                       | 1172 (82.8)            | Ref.                   | 1022 (72.2)                       | Ref.                               |
| Yes                      | 68 (82.9)              | 1.117 (0.563-2.215)   | 0.751                             | 54 (65.9)                         | 0.693 (0.405-1.186)   | 0.181                             |
| Alcohol consumption      |                        |                        |                                   |
| No                       | 1160 (83.4)            | Ref.                   | 1007 (72.4)                       | Ref.                               |
| Yes                      | 79 (74.5)              | 0.608 (0.349-1.058)   | 0.079                             | 68 (64.2)                         | 0.762 (0.467-1.244)   | 0.278                             |
| Physical activity        |                        |                        |                                   |
| Low                      | 341 (87.2)             | Ref.                   | 307 (87.5)                        | Ref.                               |
| Intermediate             | 712 (81.9)             | 0.860 (0.587-1.260)   | 0.440                             | 615 (70.8)                        | 0.887 (0.654-1.203)   | 0.442                             |
| High                     | 181 (79.0)             | 0.745 (0.453-1.223)   | 0.245                             | 151 (65.9)                        | 0.705 (0.471-1.055)   | 0.089                             |

Abbreviations: OR, odds ratio; CI, confidence interval

<sup>a</sup> Percentages are calculated in rows

All variables are included in the multivariable logistic regression model for calculating the adjusted odds ratios
and Eastern districts were more likely to receive glucose-lowering treatment (Fig. 5b).

**Control among treated**
Among diabetic participants receiving treatment, 342 (31.7%) individuals had adequate fasting glycemic control. Based on the type of treatment, glycemic control was observed among 285 (33.0%) participants receiving oral hypoglycemic agents, 30 (30.9%) participants receiving insulin injections, and 27 (22.9%) participants receiving both insulin and oral agents (P-value=0.084). A descriptive report of glycemic control across baseline characteristic subgroups is shown in 3. Diabetes control was poorest among individuals aged 45-54 years (25.9%) but increased with advancing age to reach a peak of 47.0% among those ≥75 years old (Supplementary Table 3, Fig. 4c). In contrast with awareness and treatment, diabetes control was significantly better among women than men (34.5% vs. 28.5%, respectively).

The adjusted model confirmed a significant rise in glycemic control rate in those aged ≥75 years (OR 2.475, 95% CI: 1.213-5.050) and women (OR 1.789, 95% CI: 1.295-2.471) (3). In addition, compared to illiteracy, having >12 years of education (OR 1.919, 95% CI: 1.131-2.471) was significantly associated with higher odds of having adequate glycemic control. There was no significant association between diabetes control and marital status, level of education, BMI level, pre-existing comorbidities, physical activity, tobacco use, alcohol, and opium consumption (Table 3). Unlike the treatment pattern, diabetic residents in the Northern districts of Tehran had a lower frequency of diabetes control (Fig. 5c).

**Discussion**
Based on the data from TeCS, the weighted prevalence of type 2 diabetes was approximately 16.7% among adult residents of Tehran (estimated 700,000 among 4,229,759 individuals), while approximately 25.1% had IFG (estimated 1,000,000 among 4,229,759 individuals). Furthermore, awareness, treatment, and glycemic control among treated individuals in our study population were 82.8%, 71.9%, and 31.7%, respectively.

The global prevalence of type 2 diabetes has increased over the past decades. Although the prevalence of diabetes is much lower in Asia than in Europe and North America, Middle Eastern countries such as Iran and Saudi Arabia are considered additional hot spots of the global diabetes epidemic [18, 19]. Previous population-based studies have revealed a diabetes prevalence of 7.9% to 10.6% among Iranian adults aged 25-64 years [8, 20]. Trend analysis of these studies showed a 35% increase in diabetes prevalence [8]. However, there is wide regional variability in the country. According to the 2016 STEP-wise approach to surveillance (STEPS) study in Iran, Tehran province was one of the provinces with a higher prevalence of diabetes [21]. The prevalence of diabetes was substantially higher in Tehran metropolis, a heavily-populated industrialized city within Tehran province, with diabetes being reported in 16.2% and 11.4% of men and women aged ≥25 years, respectively [21]. Thus, Tehran is one of the hot spots of diabetes in Iran, and stringent prevention strategies should be implemented to prevent its burden.

Consistent with previous studies, advancing age, male sex, and higher BMI levels were associated with an increased risk of diabetes [22–24]. Also, the prevalence of type 2 diabetes was considerably higher in participants with pre-existing comorbidities, which might be due to several mutual risk factors of metabolic diseases. Previous studies also showed a higher incidence of diabetes among individuals with low education levels [25, 26]. Despite a higher percentage of diabetes among illiterate participants in our study, high education level was not an independent protective factor against diabetes in the adjusted model. The observed educational inequality in diabetes could be partially explained by being more overweight/obese among those with lower levels of education [25, 27].

Approximately a quarter of adult residents of Tehran aged ≥35 years had IFG, and participants aged 45-54 years had the highest proportion of IFG in our study. These individuals are at increased risk of future development of diabetes, and the high proportion of young individuals with IFG is an alarm for a higher risk of mortality and vascular disease [4]. Although IFG was higher among men across all age groups, the difference in the percentage of individuals with IFG between the two sexes gradually decreased among participants aged ≥55.

Awareness and treatment were relatively high among adult residents of Tehran. While a higher percentage of younger individuals were unaware of their condition and did not receive treatment than the elderly, these indices did not significantly differ between men and women. However, in previous studies, women had a higher diabetes awareness than men [28, 29]. Also, there was a trend toward higher awareness and treatment among women over 55 compared to their male peers. We hypothesize that women, particularly after menopause, might be more sensitive to their health and physical condition than younger men. In addition, those with pre-existing comorbidities were more likely to be aware of their status, receive glucose-lowering medicines, and have more frequent health care visits.
The importance of adequate glycemic control in preventing microvascular complications of diabetes is widely-known. However, a recent study in Iran showed that only 13.2% of these patients had controlled hyperglycemia [30]. Approximately half of these patients had at least one diabetes-related complication, and a quarter had ischemic heart disease. These low glycemic control rates are not exclusive to developing societies since similar unfavorable rates are also observed in high-income countries [31]. Our findings accentuate the global importance of diabetes management in preventing disease burden.

Glycemic control was observed among less than one-third of the study population. Those receiving simultaneous insulin and oral hypoglycemic agents for the treatment of diabetes had relatively worse glycemic control, indicating a more aggressive nature of the disease. A previous study reported that diabetic patients on more intensive treatment regimens had higher mean hemoglobin A1c (HbA1c) levels [32]. Diabetes also seems more uncontrollable among men and younger individuals [5, 33]. While there is a hypothesis that early-onset type 2 diabetes might present with a more aggressive disease course, others believe younger patients probably face more difficulties adhering to a healthy lifestyle, diet, and medications than the elderly [34, 35]. Future studies should focus on more efficient and modern strategies for diabetes control [36, 37].

The lack of association between physical activity and glycemic control contrasts with the common assumption that physical activity could improve diabetes control. Although our assessment by a Likert-scale questionnaire might have biased these results, further analysis of physical activity showed that participants with low activity levels were considerably older (low active: 70.4±11.88 vs. high active: 59.5±10.60 years). It also included a higher percentage of women (low active: 64.9% vs. high active: 44.7%) than those with higher physical activity. Better diabetes control in more senior and female participants could explain why the control rate was better among those with lower physical activity. Nevertheless, a detailed assessment of physical activity in the ongoing follow-up phase of the TeCS will provide more comprehensive data.

Traditionally, the Northern half of Tehran is said to have a higher socioeconomic status than the lower half. Our data showed a higher frequency of diabetes mellitus in Tehran’s eastern and central districts. Even with the higher treatment rate, the frequency of individuals with controlled diabetes was lowest in the Northern regions. So, a public health study on the social determinants of health for diabetes in Tehran is necessary.

**Strengths and limitations**

This study has several key strengths as it was the first to investigate the epidemiology of diabetes mellitus in a large representative sample from all geographical districts of Tehran. However, this was a cross-sectional analysis and therefore has some innate limitations. We lacked data on postprandial glucose or HbA1c measurements, which could have influenced our results. HbA1c is being measured in our follow-up phase and can provide further insights. Furthermore, the diagnosis of new cases of diabetes in our study was based on a single-session FPG measurement, which might have led to potential misclassifications.

**Conclusion**

We observed a high prevalence of type 2 diabetes mellitus and IFG among the adult residents of Tehran. Despite relatively acceptable awareness and treatment rates, the high percentage of poor glycemic control might indicate a high burden of diabetes and its complications in Tehran. Public health interventions and integrated management plans for earlier diagnosis, treatment, and better control of diabetes in Tehran are required.

**Abbreviations**

BMI: Body mass index; CI: Confidence interval; FPG: Fasting plasma glucose; IFG: Impaired fasting glucose; OR: Odds ratio.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12902-022-01161-w.

**Acknowledgments**

The authors sincerely thank all nursing and administrative staff of Tehran Heart Center, who helped us in conducting this study. We are thankful to the participants of the Tehran Cohort Study for their time and cooperation.

**Authors’ contributions**

AO and AS wrote the main manuscript. AS and AJ prepared the figures. AJ cleaned the data and did the statistical analysis. AS, AO, AH, and AVF revised the manuscript. AJ, FA, and SoS designed the cohort. FA, FM, and AH contributed to data collection and management. SaS, MB, AK, and OHF supervised the project. All authors reviewed and approved the manuscript.

**Funding**

This study was financially supported by the Iranian Ministry of Health (Grant No. 1296006, program 1603003000) and Tehran Heart Center (Internal fund).

**Availability of data and materials**

The datasets generated and/or analyzed during the current study are not publicly available due to the current policy of the Tehran Cohort Study but are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
This study was approved by the deputy of research and the ethical committee of Tehran University of Medical Sciences (IR.TUMS.MEDICINE.REC.1399.074). Additionally, all participants signed a written informed consent before enrollment. All methods were carried out in accordance with the declaration of Helsinki and its updates.

Consent for publication
Not applicable.

Competing interests
None declared.

Author details
1 Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. 2 Department of Emergency Medicine, University of California, Irvine, California, USA. 3 Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. 4 Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 5 Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.

Received: 18 February 2022   Accepted: 29 September 2022

Published online: 17 October 2022

References

1. IDF. Diabetes Atlas, 9th edition [https://www.diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html]
2. Collaborators GBDRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923–94.
3. Bagherzadeh A, Nejati-Afkhaz A, Tajallizade-Khoob Y, Shafiee A, Sharifi F, Esfahani MA, Badamchizade Z, Alatab S, Fakhrazadeh H. Association of cardiac autonomic neuropathy with arterial stiffness in type 2 diabetes mellitus patients. J diabetes metab discord. 2013;12(1):55.
4. Nanayakkara N, Curtis AJ, Henriot S, Gadowski AM, Pavlov ME, Kenealy T, Owens DR, Thomas RL, Song S, Wong J, et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia. 2021;64(2):275–87.
5. Nanayakkara N, Ranasinha S, Gadowski AM, Davis WA, Flack JR, Wischer N, Andrikopoulos S, Zourngas S. Age-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes Audit. BMJ Open. 2018;8(6):e020677.
6. Collaboration NCDRF. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–30.
7. Diabetes [https://www.who.int/news-room/fact-sheets/detail/diabetes]
8. Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshadi S, Asgari F, Kamgar M, Gouya MM, Abbasi M. Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health. 2009;9:167.
9. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Ali Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107–11.
10. Safari-Faramani R, Rajati F, Tavakol K, Hormezb H, Pasdar Y, Moradinazar M, Azifi F, Aghazadeh MR, Faghizhadeh S, Haei Mehrizi AA, Cheraghi B. Socioeconomic status and prevalence of self-reported diabetes among adults in Tehran: results from a large population-based cross-sectional study (Urban HEART-2). J Endocrinol Invest. 2016;39(5):515–22.
11. Shafiee A, Saadat S, Shahnazari N, Jalali A, Alaeddini F, Haddadi M, Tadjini M, Aghazadeh MR, Rashidi A, Haghazali M, Asgari F. Prevalence, Awareness, Treatment, Control, and the Associated Factors of Diabetes in an Iranian Kurdish Population. J Diabetes Res. 2019;2019:5869206.
12. Akbarzadeh A, Salehi A, Molavi Vardanjani H, Poustchi H, Gandomkar A, Fattahi MR, Malekzadeh R. Epidemiology of Adult Diabetes Mellitus and its Correlates in Pars Cohort Study in Southern Iran. Arch Iran Med. 2019;22(11):633–9.
13. Mahtab N, Farzad H, Moshen B, Nafise D. The 10-year trend of adult diabetes, prediabetes and associated risk factors in Tehran: Phases 1 and 4 of Tehran Lipid and Glucose Study. Diabetes Metab Syndr. 2017;11(3):183–7.
14. Ramezankhani A, Harati H, Bozorgmanesh M, Tohid M, Khalili D, Azifi F, Hadaefgh F. Diabetes Mellitus: Findings from 20 Years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84784.
15. Asadi-Lari M, Khosravi A, Nedjat S, Mansournia MA, Majdzadeh R, Mohammad K, Vaez-Mahdavi MR, Faghizhadeh S, Haeri Mehrizi AA, Cheraghi B. Socioeconomic status and prevalence of self-reported diabetes among adults in Tehran: results from a large population-based cross-sectional study (Urban HEART-2). J Endocrinol Invest. 2016;39(5):515–22.
16. Shafiee A, Saadat S, Shahnazari N, Jalali A, Alaeddini F, Haddadi M, Tadjini M, Aghazadeh MR, Rashidi A, Haghazali M, Asgari F, Kamgar M, Gouya MM, Abbasi M. Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health. 2009;9:167.
17. STEPwise Approach to Surveillance Study Fact Sheet Iran [https://vizit.report/panel/stepFactSheet/en/main.html#/map]
18. Bullard KM, Cowie CC, Lessem SE, Saydah SH, Menke A, Geiss LS, Orchard TJ, Rolka DB, Imperatore G. Prevalence of Diagnosed Diabetes in Adults by Diabetes Type – United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):359–61.
19. Hu M, Wan Y, Yu L, Yuan J, Ma Y, Hou B, Jiang X, Shang L. Prevalence, Awareness and Associated Risk Factors of Diabetes in Adults Among in Xi’an, China. Sci Rep. 2017;7(1):10472.
20. Dedov I, Shestakova M, Beneditti MM, Simon D, Pakhromov I, Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90–5.
21. Mathiesen J, Jensen AKG, Andersen I, Andersen GS, Hvidtfeldt UA, Rod NH. Education and incident type 2 diabetes: quantifying the impact of differential exposure and susceptibility to being overweight or obese. Diabetologia. 2020;63(9):1764–74.
22. Sacerdote C, Ricceri F, Rolandsson O, Baldi I, Chirlaque MD, Feskens E, Bendinelli B, Ardanza E, Arriola L, Valkau R, et al. Lower educational level is a predictor of incident type 2 diabetes in European countries: the EPIC-InterAct study. Int J Epidemiol. 2012;41(4):1162–73.
23. Shang X, Li J, Tao Q, Li J, Li X, Zhang L, Liu X, Wang Q, Shi X, Zhao Y, et al. Educational level, obesity and incidence of diabetes among Chinese adult men and women aged 18–59 years old: an 11-year follow-up study. PLoS One. 2013;8(6):e66479.
24. Yue J, Mao X, Xu K, Lu L, Liu S, Chen F, Wang J. Prevalence, Awareness, Treatment and Control of Diabetes Mellitus in a Chinese Population. PLoS One. 2016;11(4):e0153791.
25. Wang C, Yu Y, Zhang X, Li Y, Kou C, Li B, Tao Y, Zhen Q, He H, Kanu JS, et al. Awareness, treatment, control of diabetes mellitus and the risk factors: survey results from northeast China. PLoS One. 2014;9(7):e103594.
26. Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami F, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.
27. Shang X, Li J, Tao Q, Li J, Li X, Zhang L, Liu X, Wang Q, Shi X, Zhao Y, et al. Educational level, obesity and incidence of diabetes among Chinese adult men and women aged 18–59 years old: an 11-year follow-up study. PLoS One. 2013;8(6):e66479.
28. Yue J, Mao X, Xu K, Lu L, Liu S, Chen F, Wang J. Prevalence, Awareness, Treatment and Control of Diabetes Mellitus in a Chinese Population. PLoS One. 2016;11(4):e0153791.
29. Wang C, Yu Y, Zhang X, Li Y, Kou C, Li B, Tao Y, Zhen Q, He H, Kanu JS, et al. Awareness, treatment, control of diabetes mellitus and the risk factors: survey results from northeast China. PLoS One. 2014;9(7):e103594.
30. Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami F, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.
31. Shah BR, Lipscombe LL, Booth GL. Glycemic Control Among People With Diabetes in Ontario: A Population-Based Cross-Sectional Study. Can J Diabetes. 2021;45(4):313–8.
32. Abbaszadeh S, Shafiee A, Bina P, Jalali A, Sadeghian S, Karimi A. Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass Surgery in Type-2 Diabetic Patients. Crit Pathw Cardiol. 2017;16(1):37–41.
33. Boo S, Yoon YJ, Oh H. Evaluating the prevalence, awareness, and control of hypertension, diabetes, and dyslipidemia in Korea using the NHS-NSC database: A cross-sectional analysis. Medicine (Baltimore). 2018;97(51):e13713.
34. Song SH, Gray TA. Early-onset type 2 diabetes: high risk for premature diabetic retinopathy. Diabetes Res Clin Pract. 2011;94(2):207–11.
35. Becie Y, Molina M, Hernandez N, Batista R, Niang S, Huet D. Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes. Diabetes Metab. 2006;32(6):611–6.
36. Heinemann L, Schramm W, Koenig H, Moritz A, Vesper I, Weissmann J, Kulzer B. Benefit of Digital Tools Used for Integrated Personalized Diabetes Management: Results From the PDM-ProValue Study Program. J Diabetes Sci Technol. 2020;14(2):240–9.
37. Kulzer B, Daenschel W, Daenschel I, Schramm W, Messinger D, Weissmann J, Vesper I, Parkin CG, Heinemann L. Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program. Diabetes Res Clin Pract. 2018;144:200–12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.